Literature DB >> 8407251

Diagnostics of persistent viruses: human cytomegalovirus as an example.

G Jahn1, B Plachter.   

Abstract

Infections with persistent viruses such as herpesviruses have become of significant clinical importance with the increasing number of immunocompromised patients at risk to suffer from severe disease. As antiviral chemotherapy is available for herpesvirus infections, the diagnostic methods for rapid and sensitive detection of symptomatic infection have been developed and recently refined. In human cytomegalovirus (HCMV), the use of recombinant viral antigens provides a rationale to improve serological assays. This may be of use for the discrimination of primary versus secondary infection. Early diagnosis of symptomatic HCMV infection in immunosuppressed patients can be most effectively achieved by the detection of a viral tegument protein, pp65, in peripheral blood leukocytes. This early diagnosis has been shown to be of major importance for the effective treatment of these patients. HCMV infection in solid organs can be demonstrated by immunohistochemistry using monoclonal antibodies against viral proteins. HCMV involvement in diseases of the central nervous system in AIDS patients can be verified by the detection of very small amounts of HCMV DNA in cerebrospinal fluid by polymerase chain reaction. This method may prove useful for monitoring HCMV encephalitis and neuropathy.

Entities:  

Mesh:

Year:  1993        PMID: 8407251     DOI: 10.1159/000150296

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  2 in total

1.  Immunoglobulin A-specific serodiagnosis of acute human cytomegalovirus infection by using recombinant viral antigens.

Authors:  R Vornhagen; W Hinderer; H H Sonneborn; G Bein; L Matter; T H The; G Jahn; B Plachter
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

2.  Polo-like kinase 1 as a target for human cytomegalovirus pp65 lower matrix protein.

Authors:  A Gallina; L Simoncini; S Garbelli; E Percivalle; G Pedrali-Noy; K S Lee; R L Erikson; B Plachter; G Gerna; G Milanesi
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.